Compare Marqeta Inc (MQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Marqeta Inc trades at $18.39 (market cap $1.93B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.5× Marqeta Inc's market cap, and Marqeta Inc is more actively traded (915,027 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MQ | TVTX | |
|---|---|---|
Market Cap | $1.93B | $4.88B |
Volume | 915,027 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $20.32 | $67.52 |
52-Week Low | $15.04 | $26.79 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.25B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.56, up 1.48% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported three consecutive quarterly EPS beats, with Q3 2026 results expected soon. Revenue has recovered from $507M in 2024 to $625M in 2025, though net income remains negative. Positive cash flow trends emerged in 2025, with net cash flow turning positive at $86M.
The outlook is mixed: strong operational momentum and partnerships (e.g., with Google and BVNK) support growth, but high valuation ratios (P/E 206.22) and thin net margins (1.53%) pose risks. Analyst consensus is cautious with a $11.38 price target, implying downside, yet institutional sentiment is divided amid earnings improvements.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
